Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Atherosclerotic cardiovascular disease (ASCVD) is the leading global cause of mortality.
• Elevated LDL cholesterol is a primary risk factor for ASCVD.
• Statins are the primary therapy for lowering LDL cholesterol but are not suitable for all patients due to intolerance.

Purpose of the Study:

• To evaluate the efficacy and safety of bempedoic acid in statin-intolerant patients.
• To assess bempedoic acid's role in preventing major adverse cardiovascular events (MACE).
• To determine bempedoic acid's utility in both primary and secondary cardiovascular prevention.

Main Methods:

• The CLEAR Outcomes trial was a Phase 3 clinical study.
• Enrolled statin-intolerant patients at high risk for or with existing cardiovascular events.
• Bempedoic acid, an ATP citrate lyase (ACL) inhibitor, was compared against a placebo.

Main Results:

• The primary endpoint, a composite of MACE, occurred less frequently in the bempedoic acid group compared to placebo.
• Bempedoic acid demonstrated a favorable safety profile in most subjects.
• The LDL cholesterol-lowering and cardiovascular event reduction effects were modest.

Conclusions:

• Bempedoic acid is a viable monotherapy for cardiovascular event prevention in statin-intolerant individuals.
• Combination therapy with bempedoic acid and other lipid-lowering agents may enhance LDL cholesterol reduction.
• Further research into combination therapies could optimize cardiovascular risk management.